Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

– – Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis – – Phase 3 studies of CAEL-101 in AL amyloidosis are underway – BORDENTOWN, N.J. & BOSTON – November 04, 2020 11:55 AM Eastern Standard Time – (BUSINESS WIRE)–Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the

Read More

Fortress Biotech forms a new subsidiary, Caelum Biosciences, Inc., to develop a novel treatment for AL Amyloidosis

Download the Press Release (PDF) Caelum Program Evaluating CAEL‐101 (11‐1F4) for AL Amyloidosis In‐licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL‐101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL‐101 is safe and well tolerated; 67 percent of patients showed improvement in organ function. Michael Spector to Serve as Chief Executive Officer NEW YORK, NY – January 4, 2017 – Fortress Biotech, Inc. (Nasdaq: FBIO)

Read More